The molecular basis of myeloproliferative neoplasms (MPNs) came into the limelight in 2005 with the identification of JAK2 mutations in almost all cases of polycythemia vera and most essential thrombocythemia (ET) [1–4]. Here, JAK2 is linked to myeloproliferative disorder.